Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.

Minal BarvePhylicia AaronLuisa ManningErnest BognarGladice WallravenStaci HorvathLaura StanberyJohn J Nemunaitis

Published in: Clinical Medicine Insights. Oncology (2022)

Vigil plus durvalumab was well tolerated and showed promising clinical activity in advanced BRCA-wt TNBC and stage III-IV recurrent/refractory OC patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
acute lymphoblastic leukemia
peritoneal dialysis
prognostic factors
diffuse large b cell lymphoma
breast cancer risk